AP
SYRS

AlpInvest Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

AlpInvest Partners’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,500
Closed -$89K – 17
2020
Q1 		$89K Buy
+1,500
New +$102K 0.1% 19

Other funds holding SYRS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlpInvest Partners's SYRS Position: Q2 2020 in Review

AlpInvest Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2020, closing a stake of 1,500 shares — an estimated $89K sold.

AlpInvest Partners first reported a position in SYRS in Q1 2020 and held it in 1 quarter. The position peaked at $89K in Q1 2020. 79 funds tracked by Wall St. Rank hold SYRS as of Q2 2020.

  • AlpInvest Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • AlpInvest Partners sold 1,500 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $89K.
  • AlpInvest Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • AlpInvest Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $89K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on AlpInvest Partners's 13F filing for Q2 2020, filed 13 Aug 2020.